Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Summary
Zai Lab has shared preliminary data from the initial phase of a clinical trial testing its experimental antibody for atopic dermatitis. Results from healthy volunteers indicate that the treatment effectively blocks a key biological pathway and features an extended half-life. These findings support the potential for quarterly maintenance dosing in future evaluations.
Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis. Strong Biomarker Inhibition And Extended Half-Life Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway. A single dose of 200 mg or higher inhibited phosphorylated STAT6,…
Source: Read the full story at Top Stories Feed